Inhibikase Therapeutics, Inc. (IKT) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -12.06M | -7.52M | -10.59M | -5.57M | -4.1M | -5.35M | -4.88M | -5.05M | -3.87M | -3.44M | -4.11M | -4.57M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | -99999900% | -5159.16% | -3921.82% |
| Operating CF Growth % | -193.89% | -40.6% | -117.02% | -10.29% | -6.12% | -55.28% | -18.9% | -10.71% | 35.25% | 3.2% | 25.43% | -4.81% |
| Net Income | -16.38M | -12.73M | -11.93M | -9.92M | -13.68M | -12.13M | -5.78M | -4.96M | -4.65M | -4.18M | -4.6M | -5.78M |
| Depreciation & Amortization | 0 | 0 | 23.69K | 24.16K | 12.65K | 6.57K | 6.57K | 6.57K | 6.57K | 6.57K | 6.58K | 159.2K |
| Stock-Based Compensation | 0 | 4.53M | 0 | 4.21M | 2.04M | 7.91M | 148.02K | 30.7K | 53.43K | 122.25K | 129.78K | 124.84K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -663.27K |
| Other Non-Cash Items | 4.37M | 275.7K | 3.46M | -358.42K | 6.19M | 0 | 0 | 0 | 0 | 14.26K | 17.28K | 663.27K |
| Working Capital Changes | -50.37K | 409.2K | -2.15M | 466.81K | 1.33M | -1.13M | 742.37K | -132.03K | 722.62K | 592.44K | 336.46K | 928.53K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 79.6K | -15.08K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 429.25K | 537.53K | -1.98M | 911.83K | 680.82K | -1.06M | 453.43K | 396.43K | 479.27K | -87.79K | -19.59K | -204.93K |
| Cash from Investing | -80.48M | -98.85K | -28.75M | 9.84M | 21.05M | -38.76M | 2.53M | 2.54M | -3.31M | -2.12M | 17.06M | 2.55M |
| Capital Expenditures | 0 | -452.02K | 0 | 0 | -452.02K | 0 | 0 | 0 | 0 | 0 | 0 | -14.24K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | 12.23% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.24K |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 452.02K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -14.24K |
| Cash from Financing | 2.9M | 108.57M | -134.13K | 31.77K | 0 | 99.68M | 181.95K | 3.24M | 367K | -138.1K | 70 | -35.99K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 2.9M | 108.18M | 250.93K | 150 | 0 | 99.68M | 181.95K | 3.21M | 397.61K | 452 | 70 | -35.99K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 385.06K | -385.06K | 31.62K | 0 | 0 | 0 | 30.61K | -30.61K | -138.56K | 0 | 0 |
| Net Change in Cash | -89.65M | 100.95M | -39.47M | 4.3M | 16.95M | 55.58M | -2.17M | 733.11K | -6.81M | -5.7M | 12.96M | -2.05M |
| Free Cash Flow | -12.06M | -7.97M | -10.59M | -5.57M | -4.1M | -5.35M | -4.88M | -5.05M | -3.87M | -3.44M | -4.11M | -4.58M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | -99999900% | -5159.16% | -3934.05% |
| FCF Growth % | -193.89% | -49.06% | -117.02% | -10.29% | -6.12% | -55.28% | -18.9% | -10.37% | 35.25% | 3.2% | 28.04% | -4.11% |
| FCF per Share | -0.12 | -0.08 | -0.12 | -0.06 | -0.05 | -0.08 | -0.55 | -0.67 | -0.61 | -0.56 | -0.77 | -0.88 |
| FCF Conversion (FCF/Net Income) | 0.74x | 0.59x | 0.89x | 0.56x | 0.30x | 0.44x | 0.84x | 1.02x | 0.83x | 0.82x | 0.89x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |